{
  "docId": "019dd923-5f69-752d-a9b6-2758ff8024b8",
  "docSlug": "IOYPUci1JeH6qtF9hngI",
  "documentTitle": "See the 21-slide pitch deck a biotech startup used to convince investors like Pfizer to bet on fixing damaged organs",
  "authorId": "Pitchdecks",
  "authorName": "Agomab Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 16,
  "pageCount": 21,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "Uses a before-after-bridge style logic to frame the problem and solution.",
  "elementsJson": [
    "infographic",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b6-2758ff8024b8/16",
  "deckHref": "/decks/019dd923-5f69-752d-a9b6-2758ff8024b8",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b6-2758ff8024b8.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b6-2758ff8024b8#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.02,
        "y": 0.275
      },
      "kind": "image",
      "text": "Diagram of HGF binding to MET receptor and downstream signaling pathways (SRC/FAK, MEK/ERK, PI3K/AKT, STAT3)",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68d0b3a9-9677-49ca-afd9-e24f53e184d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.68,
        "y": 0.3
      },
      "kind": "list",
      "text": "AGMB-101: Full MET receptor agonist mAb, Use of full MET biology, Acute & severe chronic indications; AGMB-102: Partial MET receptor agonist mAb, Avoiding proliferative effect, Chronic fibrotic indications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0061964-f240-4507-a2a7-c939e733b6ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.34,
        "y": 0.3
      },
      "kind": "list",
      "text": "HGF has a very short half-life which makes targeting difficult (2-5min); Complex 3D structure makes binding difficult; Proliferative effect of HGF needs to be balanced",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0036f4d-ba0b-4c99-ab7e-ecf967e27248",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.12,
        "y": 0.07
      },
      "kind": "title",
      "text": "Agomab's HGF targeting platform",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1beba0a0-1f4b-4bf6-9da3-cb42c4d9fdf3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "86829c82-b944-40eb-a23a-d11592cc745d",
      "evidence": "The slide structure moves from the biological target/problem to the specific therapeutic solutions.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}